[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340145-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340145-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-importance-of-predictive-biomarkers-and-their-correlation-with-the-response-to-immunotherapy-in-solid-tumorsimpact-on-clinical-practice","The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors—Impact on Clinical Practice","","Immunotherapy has reshaped treatment for multiple solid tumors, delivering meaningful antitumor activity with manageable safety and often durable responses, yet benefit is uneven across patients. Predictive biomarkers are therefore essential to identify individuals most likely to respond to immune checkpoint inhibitors and to guide more personalized oncology care. The work reviews key biomarker candidates—including PD-L1 expression, tumor mutational burden, microsatellite instability, gene expression profiles, and circulating tumor DNA—while emphasizing practical barriers such as standardization, validation, regulatory approval, and cost-effectiveness, and highlighting gaps regarding links between local and systemic immunity, treatment response, and survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-importance-of-predictive-biomarkers-and-their-correlation-with-the-response-to-immunotherapy-in-solid-tumorsimpact-on-clinical-practice/340145/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-importance-of-predictive-biomarkers-and-their-correlation-with-the-response-to-immunotherapy-in-solid-tumorsimpact-on-clinical-practice/340145.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are predictive biomarkers needed for immunotherapy in solid tumors?","Question",{"text":63,"@type":64},"Not all patients benefit from immunotherapy, so predictive biomarkers help identify those most likely to respond to immune checkpoint inhibitors and optimize clinical use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which predictive biomarkers are discussed as potential predictors of ICI response?",{"text":68,"@type":64},"The document highlights PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), gene expression profiles, and circulating tumor DNA (ctDNA).",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges limit clinical implementation of predictive biomarkers?",{"text":72,"@type":64},"Key issues include standardization, validation, regulatory approval, and cost-effectiveness. The text also notes limited knowledge about how local and systemic immune responses correlate with therapy outcomes and survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340145,1790151572,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","biomedicines  \nReview  \nThe Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors—Impact on Clinical Practice  \nRaluca Ioana Mihaila 1,2, *, Adelina Silvana Gheorghe 1,2, Daniela Luminita Zob 2 and Dana Lucia Stanculeanu 1,2  \nCitation: Mihaila, R.I.; Gheorghe, A.S.; Zob, D.L.; Stanculeanu, D.L. The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors—Impact on Clinical Practice. Biomedicines 2024, 12, 2146 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biomedicines12092146  \nAcademic Editor: Yu-Jen Chen  \nReceived: 19 August 2024  \nRevised: 12 September 2024  \nAccepted: 20 September 2024  \nPublished: 22 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Oncology,“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania  \n2 Department of Medical Oncology I,“Prof. Dr. Alexandru Trestioreanu”, Institute of Oncology,  \n022328 Bucharest, Romania  \n* Correspondence: [raluca-ioana.mihaila@drd.umfcd.ro or dr.ralucamihaila@yahoo.com](raluca-ioana.mihaila@drd.umfcd.ro or dr.ralucamihaila@yahoo.com)  \nAbstract: Background/Objectives: Immunotherapy has changed the therapeutic approach for various solid tumors, especially lung tumors, malignant melanoma, renal and urogenital carcinomas, demonstrating significant antitumor activity, with tolerable safety profiles and durable responses. However, not all patients benefit from immunotherapy, underscoring the need for predictive biomarkers that can identify those most likely to respond to treatment. Methods: The integration of predictive biomarkers into clinical practice for immune checkpoint inhibitors (ICI) holds great promise for personalized cancer treatment. Programmed death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), microsatellite instability (MSI), gene expression profiles and circulating tumor DNA (ctDNA) have shown potential in predicting ICI responses across various cancers. Results: Challenges such as standardization, validation, regulatory approval, and cost-effectiveness must be addressed to realize their full potential. Predictive biomarkers are crucial for optimizing the clinical use of ICIs in cancer therapy. Conclusions: While significant progress has been made, further research and collaboration among clinicians, researchers, and regulatory institutes are essential to overcome the challenges of clinical implementation. However, little is known about the relationship between local and systemic immune responses and the correlation with response to oncological therapies and patient survival.  \nKeywords: immunotherapy; biomarkers; TMB; MSI; ctDNA; local immunity; systemic immunity  \n1. Introduction  \nCarcinogenesis and tumor growth are associated with chronic inflammation and stimulation of the host’s immune system. The chronic systemic inflammatory response has been extensively investigated in relation to the progression and prognosis of specific tumors. Thus, immunomodulatory therapies have emerged as effective antineoplastic therapeutic strategies. Immunotherapy (check point inhibitors anti PD-1, PD-L1 or anti CTLA-4) has demonstrated significant antitumor activity, with tolerable safety profiles and durable responses in various neoplasia.  \nCurrently, immunotherapy is used either in monotherapy/combination of immunotherapeutic agents or in addition to antineoplastic agents (chemotherapy, targeted therapy) in first-line treatment or subsequent lines, mainly in lung, melanoma, ENT, breast, bladder cancers, etc. The immune system is divided into two main branches","cbCaieHunC0B5Tbr","https://ap.wps.com/l/cbCaieHunC0B5Tbr","pdf",338620,15,"English","# Abstract\n# Introduction\n## Immunotherapy and solid tumors\n## Innate and adaptive immune systems\n## Rationale for predictive biomarkers","[{\"question\":\"Why are predictive biomarkers needed for immunotherapy in solid tumors?\",\"answer\":\"Not all patients benefit from immunotherapy, so predictive biomarkers help identify those most likely to respond to immune checkpoint inhibitors and optimize clinical use.\"},{\"question\":\"Which predictive biomarkers are discussed as potential predictors of ICI response?\",\"answer\":\"The document highlights PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), gene expression profiles, and circulating tumor DNA (ctDNA).\"},{\"question\":\"What challenges limit clinical implementation of predictive biomarkers?\",\"answer\":\"Key issues include standardization, validation, regulatory approval, and cost-effectiveness. The text also notes limited knowledge about how local and systemic immune responses correlate with therapy outcomes and survival.\"}]","The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors—Impact on Clinical Practice | PDF",1790034492,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f35ef03bbacad6e9015602321b8f8ed9.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4080635657af71ca669f5ecd30825dd6.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b958aec33d79fcb4974d92b767514b9.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a578d9bf73a89c040bcfe06abfe90b0.webp",980,1385]